Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Telitacicept, a first-in-class dual B-cell targeting therapy, is showing impressive staying power in generalized myasthenia gravis. A post hoc analysis of 48-week phase 3 data found that ~42% of patients reached minimal symptom expression, and most held onto those gains over time. A global phase 3 trial is fully enrolled, with topline results expected in early 2027.
Telitacicept, a fusion protein that simultaneously neutralizes two key B-cell survival signals (BAFF and APRIL), is delivering deep and durable benefits in generalized myasthenia gravis (gMG). A post hoc analysis of 48-week phase 3 data — presented at the 2026 AANEM Annual Meeting — showed that clinical responses not only held but continued to deepen the longer patients stayed on the drug, a meaningful distinction in a chronic disease where sustained control matters as much as initial improvement.
The drug's dual mechanism sets it apart from most existing MG therapies, which act downstream by clearing circulating antibodies or blocking complement. Telitacicept works further upstream, depleting autoantibody-producing plasma cells while also blocking B-cell repopulation — essentially preventing the immune system from resetting its attack on the neuromuscular junction.
By the Numbers:
94% achieved at least a 5-point MG-ADL improvement by week 48
Why it matters: With a global phase 3 trial (UPSTREAM MG) fully enrolled and topline data expected in the first half of 2027, telitacicept could become a significant new option for gMG patients — particularly those seeking long-term, near-symptom-free disease control rather than just short-term relief.
